Evidence map›Paper›PMID 32139705›Full record

ArticleScientific reports2020

MicroRNA-144 represses gliomas progression and elevates susceptibility to Temozolomide by targeting CAV2 and FGF7.

Zhi-Qin Liu, Jing-Jing Ren, Jun-Long Zhao, Jian Zang, Qian-Fa Long, Jing-Jing Du, Xiao-Tao Jia, Nai-Bing Gu, Zheng-Li Di, Yi-Hua Qian and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Zhi-Qin Liu *Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Jing-Jing Ren *Department of Haematology, Xi'an Central Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, China.
Jun-Long Zhao *Department of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an, China.
Jian ZangDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Qian-Fa LongMini-invasive Neurosurgery and Translational Medical Center, Xi'an Central Hospital, Xi'an Jiaotong University, Xi'an, China.
Jing-Jing DuDepartment of Neurology, Xi'an Central Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, China.
Xiao-Tao JiaDepartment of Neurology, Xi'an Central Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, China.
Nai-Bing GuDepartment of Neurology, Xi'an Central Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, China.
Zheng-Li DiDepartment of Neurology, Xi'an Central Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, China.
Yi-Hua QianDepartment of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China. qianyh38@mail.xjtu.edu.cn.
San-Zhong LiDepartment of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China. sunny_3c@126.com.
Xi'an Jiaotong University · CNXian Central Hospital · CNAir Force Medical University · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant gliomas are the most common tumor in central nervous system with poor prognosis. Due to the limitation of histological classification in earlier diagnosis and individualized medicine, it is necessary to combine the molecular signatures and the pathological characteristics of gliomas. Lots of microRNAs presented abnormal expression in gliomas and modulated gliomas development. Exploration the miRNAs profile is helpful for the diagnosis, therapy and prognosis of gliomas. It has been demonstrated that miR-144 plays important roles in solid tumors. However, the detail mechanisms remained unrevealed. In this study, we have demonstrated the level of miR-144 decreased in glioma tissues from patients, especially in gliomas with higher grades. MiR-144 was also validated have lower expression in glioma cell lines compared with cortical neuron cell by using qRT-PCR. The in vitro functional experiment indicated miR-144 improved gliomas progression through repressing proliferation, sensitizing to chemotherapeutics and inhibiting metastasis. We further identified fibroblast growth factor 7 (FGF7) and Caveolin 2 (CAV2) were target genes of miR-144 by luciferase reporter assay and western blotting. The mechanisms study suggested forced FGF7 expression elevated Akt activation and decreased reactive oxygen species (ROS) generation. The MTT and cell cycle assay indicated miR-144 suppressed glioma cells proliferation through modulating FGF mediated Akt signaling pathway. Meanwhile, miR-144 promoted Temozolomide (TMZ) induced apoptosis in glioma cells via increasing ROS production by using FACS. On the other hand, CAV2, as another target of miR-144, accelerated glioma cells migration and invasion via promoting glioma cells EMT progress. Retrieved expression of FGF7 or CAV2 rescued the proliferation and migration function mediated by miR-144. Furthermore, the in vivo experiments in PDX models displayed the anti-tumor function of miR-144, which could be retrieved by overexpression of FGF7 and CAV2. Taken together, these findings indicated miR-144 acted as a potential target against gliomas progression and uncovered a novel regulatory mechanism, which may provide a new therapeutic strategy and prognostic indicator for gliomas.

Indexed as

AnimalsApoptosisBlotting, WesternCaveolin 2Cell CycleCell LineCell Line, TumorCell MovementCell ProliferationFibroblast Growth Factor 7GliomaHumansIn Vitro TechniquesMaleMiceMice, Inbred BALB CCAV2 protein, humanCaveolin 2FGF7 protein, humanFibroblast Growth Factor 7MicroRNAsMIRN144 microRNA, mouseReactive Oxygen Species

Identifiers

PMID32139705
PMCPMC7058039
OpenAlexW3009730465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.